1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs

L E Stopfer; A D D'Souza; F M White

doi:10.1016/j.iotech.2021.100042

1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs

Immunooncol Technol. 2021 Oct 13:11:100042. doi: 10.1016/j.iotech.2021.100042. eCollection 2021 Oct.

Authors

L E Stopfer^{1

2}, A D D'Souza^{2

3}, F M White^{1

2}

Affiliations

¹ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA.
² Koch Institute for Integrative Cancer Research, Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, USA.
³ Program in Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of Technology, Boston, USA.

Abstract

Quantitative mass-spectrometry-based methods to perform relative and absolute quantification of peptides in the immunopeptidome are growing in popularity as researchers aim to measure the dynamic nature of the peptide major histocompatibility complex repertoire and make copies-per-cell estimations of target antigens of interest. Multiple methods to carry out these experiments have been reported, each with unique advantages and limitations. This article describes existing methods and recent applications, offering guidance for improving quantitative accuracy and selecting an appropriate experimental set-up to maximize data quality and quantity.

Keywords: HLA; MHC; antigen presentation; immunopeptidomics; mass spectometry.

Publication types

Review

Abstract

Publication types

Grants and funding